Date of event: estimated.Date of implant: estimated.The device was not returned for analysis.A review of the lot history record and complaint history could not be conducted because the lot number was not provided.The patient effects listed are consistent with the product risk profile and are therefore expected.A conclusive cause for the difficulties listed can not be determined based on the limited information available.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling of the device.The other events mentioned in the article are filed under other mfr report numbers.Article title "one-year results following a pre-specified absorb implantation strategy in st-elevation myocardial infarction (bvs stemi strategy it study)".
|
It was reported through a research article identifying the absorb bioresorbable vascular scaffold (bvs) that after pre-dilatation of the lesion in the proximal right coronary artery, a 3.5x28mm absorb scaffold was implanted and post dilated.Two months post-implant, the patient experienced a myocardial infarction and scaffold thrombosis.Treatment included percutaneous coronary intervention with a drug-eluting bioresorbable scaffold implanted.Details are listed in the attached article, titled "one-year results following a pre-specified absorb implantation strategy in st-elevation myocardial infarction (bvs stemi strategy-it study)".Please see article for additional information.Specifically, this event captures case 4 from table 3 in the article.
|